Wordt geladen...

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

Bevacizumab is a monoclonal antibody that binds and neutralizes vascular endothelial growth factor (VEGF)-A, a key player in the angiogenesis pathway. Despite benefits of bevacizumab in cancer therapy, it is clear that the VEGF pathway is complex, involving multiple isoforms, receptors, and alternat...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteur: Saif, Muhammad Wasif
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Dove Medical Press 2013
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3685399/
https://ncbi.nlm.nih.gov/pubmed/23807861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S45193
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!